Covaxin

The Hyderabad-based biotech company clarified late at night that in the "rush" to develop vaccines and file the necessary patents, BBIL had forgotten to include ICMR's name in the original filings.

‘Incorrect, Misleading’: ICMR Seeks Retraction Of BHU Study On Covaxin Side Effects, Warns Of Legal Action

ICMR said that it has noticed that the BHU's authors have acknowledged ICMR in similar previous papers without permission. It has asked for an explanation on why ICMR should not seek legal and administrative action against the authors. The BHU said it is aware of the communication made by the ICMR to the individuals concerned and its Institute of Medical Sciences is looking into the matter. The university also added that it is working on improving its research ecosystem

ICMR discredits BHU study on Covaxin safety for methodological flaws

Study participants were contacted telephonically one year after vaccination and their responses were recorded without any confirmation with clinical records or by physician examination

Over 30% of Covaxin recipients report 'adverse events' in BHU study. What are the side effects?

Out of 926 participants of the study, around 50 percent complained of infections during the follow-up period, which was dominated by viral upper respiratory tract infections, the research showed.

Ocugen-Bharat Biotech COVID vaccine meets main goals in US trial

The vaccine, sold under brand name Covaxin, showed an immune response in individuals who had not received a COVID vaccine previously as well as those vaccinated with mRNA vaccines by Pfizer Inc and Moderna Inc, meeting its main goals, Ocugen said.

Bharat Biotech’s Covaxin inching closer to US launch plan?

Covaxin was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the US with no vaccine-related serious adverse events, Bharat Biotech’s partner in the country has announced

Covishield immune responses against Covid variants higher than Covaxin: Study

Vaccination following exposure to the Delta or Omicron variants of SARS-CoV-2 is likely to affect the quality, quantity and duration of immune responses.

Govt rubbishes reports on approval for Covaxin due to political pressure

There have been media reports claiming that Bharat Biotech, manufacturer of the indigenous COVID-19 vaccine Covaxin, had to skip certain processes and 'speed' up clinical trials due to political pressure, the ministry said.

50 million doses of Covaxin set to expire early 2023 due to poor off take

As the infection rate has been sturdily declining globally, exports of Covaxin were negatively impacted with poor off take by foreign countries.

Can Bharat Biotech's intranasal vaccine prevent COVID-19 infection and transmission? 

With Bharat Biotech completing clinical trials of its vaccine candidate, hopes have been raised about the availability of intranasal vaccine as a booster dose just as the number of daily Covid-19 cases and test positivity rate in parts of India have started surging over the last few weeks.  

Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.

Covaxin booster doses effective against variants, shows study

The findings of the study have been published in the high-impact scientific journal Nature.

Political will at the top and community participation at the bottom drove India's COVID-19 vaccination campaign: Dr N K Arora

On July 17, India administered its 2 billionth COVID-19 vaccine dose, 18 months after the mammoth vaccination drive against coronavirus was launched. Of the total doses administered, 51 percent doses were given to women and 71 percent vaccination centres were in rural areas

Moneycontrol Selects: Top stories this evening

Our specially curated package of the most interesting articles to help you stay at the top of your game.

NTAGI's technical sub-committee recommends use of Corbevax, Covaxin for children between 5-12 years

Biological E’s Corbevax has been recommended for administration in 5 to 12 years old children, while the Bharat Biotech’s Covaxin has been recommended for children in 6-12 years’ age group.

COVID-19 shots administered in India about to overtake count in all of Europe, North America

This is a remarkable feat, considering that all the vaccine doses administered in the country are made locally

Covaxin proven safe for children of 2-18 years age group in phase III study: Bharat Biotech

In a phase II/III research, Bharat Biotech International Ltd's COVID-19 vaccine Covaxin was found to be safe, well-tolerated, and highly immunogenic in children and adolescents aged 2 to 18 years.

Covaxin more effective for kids and adolescents than adults, Bharat Biotech publishes trial data

The company said that no adverse events of special interest have been reported to date. However, a supplementary surveillance study is going on, which will provide more information on rarer adverse events

We are able to predict pandemic based on changes in virus, other signals: Bharat Biotech founder

Bharat Biotech, the manufacturer of Covaxin, announced on Thursday that his business can now forecast a pandemic based on changes in viral and related signals.

Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

The protective efficacy of Bharat Biotech's Covaxin following two and three-dose immuniszations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a Syrian hamster model (animal model to study human-associated diseases), it said.

Paraguay cancels order for one million Covaxin doses citing quality issues: Reports

Bharat Biotech did not immediately react to the development, but company sources reportedly said that all export orders already stand cancelled as the production has been halted.

Top virologists weigh in for Corbevax booster after primary vaccination with Covishield, Covaxin 

The pharma regulator has approved the first mix-and-match of COVID-19 vaccines in India, but the final say-so lies with the government 

Germany to recognise Bharat Biotech’s Covaxin for travel from June 1

German Ambassador to India and Bhutan, Walter J Lindner on Thursday said the government of the European nation will start recognizing Bharat Biotech’s COVID-19 vaccine for travel purpose there from June 1.

FDA lifts hold on Covaxin's clinical trials in US

The FDA’s earlier decision, in April, to put on hold the trials was based on the US firm’s decision to voluntarily implement a temporary pause in dosing participants of the jab, following the World Health Organisation’s observations on Covaxin manufacturing plants in India.

Covid-19: 10 crore doses of SII's Covovax approved for exports by govt lab, stock rolled out for teens

Covovax, the Covid-19 vaccine manufactured by the Serum Institute of India under licence from US firm Novavax, will be available at Rs 225 per dose, excluding taxes, at private healthcare facilities.